GlobeNewsWire · TNGX · October 23, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Get the app for more

Explore stock news, insights and company research.